CN Patent

CN111821299A — 噻吩衍生物用于治疗免疫球蛋白E（IgE）介导的疾病的应用

Assigned to Tianjin Hemay Pharmaceutical SCI Tech Co Ltd · Expires 2020-10-27 · 6y expired

What this patent protects

公开了N‑(5‑(1‑(3‑乙氧基‑4‑甲氧基苯基)‑2‑(甲砜基)乙基)‑4，6‑二氧‑5，6‑二氢‑4H‑噻吩[3，4‑c]吡咯‑1‑基)乙酰胺、其立体异构体或其药物可接受的盐在治疗免疫球蛋白E(IgE)介导的疾病的方法的应用。

USPTO Abstract

公开了N‑(5‑(1‑(3‑乙氧基‑4‑甲氧基苯基)‑2‑(甲砜基)乙基)‑4，6‑二氧‑5，6‑二氢‑4H‑噻吩[3，4‑c]吡咯‑1‑基)乙酰胺、其立体异构体或其药物可接受的盐在治疗免疫球蛋白E(IgE)介导的疾病的方法的应用。

Drugs covered by this patent

Patent Metadata

Patent number
CN111821299A
Jurisdiction
CN
Classification
—
Expires
2020-10-27
Drug substance claim
No
Drug product claim
No
Assignee
Tianjin Hemay Pharmaceutical SCI Tech Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.